Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CSPC Pharma Out-Licenses Nectin-4 ADC to Corbus in $692 Million Deal

publication date: Feb 14, 2023

A CSPC Pharma subsidiary out-licensed ex-China rights for a Nectin-4 antibody drug conjugate to Boston’s Corbus Pharma in a heavily backloaded $692.5 million deal. Corbus will have rights to SYS6002 in the US, EU and Australian markets. CSPC Megalith Biopharma has started a China Phase I dose-escalating trial of the candidate in patients with advanced solid tumor cancers. CSPC will receive a $7.5 million upfront payment and up to $685 million in milestones, plus royalties on sales. CSPC plans to aim SYS6002 at urothelial cancer initially. More details....

Stock Symbols: (HK: 01093) (NSDQ: CRBP)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here